13,140 reports of this reaction
3.0% of all DULOXETINE HYDROCHLORIDE reports
#5 most reported adverse reaction
DIZZINESS is the #5 most commonly reported adverse reaction for DULOXETINE HYDROCHLORIDE, manufactured by Eli Lilly and Company. There are 13,140 FDA adverse event reports linking DULOXETINE HYDROCHLORIDE to DIZZINESS. This represents approximately 3.0% of all 434,529 adverse event reports for this drug.
Patients taking DULOXETINE HYDROCHLORIDE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for DULOXETINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for DULOXETINE HYDROCHLORIDE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 13,140 FDA reports for DULOXETINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 3.0% of all adverse event reports for DULOXETINE HYDROCHLORIDE, making it a notable side effect.
If you experience dizziness while taking DULOXETINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.